A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03628924 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

184

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: Guselkumab dose 1
DRUG: Guselkumab dose 2
DRUG: Guselkumab dose 3
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC